CLAIM #69432 · AbbVie Inc (ABBV) · 2026Q2 earnings call · Jul 31, 2026 · due Dec 31, 2026
“We are also preparing for the potential approval of our subcutaneous induction dosing option for Crohn's later this fall, which is supported by very strong data, particularly in the frontline where we observe the highest levels of endoscopic response seen in the category.”
Jeff Stewart · Chief Commercial Officer
PENDING
graded after results covering Dec 31, 2026 are reported
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2026Q2 earnings call.